Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

jbuffett62

Rank: Treasurer [?]

Points: 480 [?]

Votes: 13 Score: 2.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

RVXoldtimer

posted on Dec 22, 2020 10:08AM

Plus, we have no info on duration of immunity after vaccination. An RVX pill a day, keeps the covid at bay.

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply